Anixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary name

Anixa Biosciences (ANIX) announced that the International Nonproprietary Names, or INN, Expert Committee of the World Health Organization, or WHO, approved “liraltagene autoleucel” for the non-proprietary name of the company’s novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The INN nomenclature scheme for CAR-T cell therapies follows a two-word structure describing the gene and cell component. Each INN name is unique and is used to identify active pharmaceutical ingredients. Each active substance that is to be marketed as a pharmaceutical must be granted a unique name of worldwide acceptability to ensure the clear identification, safe prescription and dispensing of medicines to patients. Anixa will transition to the use of liraltagene autoleucel, or lira-cel, in future communications.